1. Home
  2. EVAX vs GRML Comparison

EVAX vs GRML Comparison

Compare EVAX & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.24

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.21

Market Cap

29.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EVAX
GRML
Founded
2008
N/A
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.9M
29.2M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
EVAX
GRML
Price
$3.24
$0.21
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$11.67
N/A
AVG Volume (30 Days)
11.4K
7.2M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$328.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.52
$0.16
52 Week High
$12.15
$0.55

Technical Indicators

Market Signals
Indicator
EVAX
GRML
Relative Strength Index (RSI) 61.23 47.25
Support Level $2.93 $0.17
Resistance Level $3.61 $0.30
Average True Range (ATR) 0.16 0.02
MACD 0.06 0.00
Stochastic Oscillator 83.61 53.14

Price Performance

Historical Comparison
EVAX
GRML

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: